Last reviewed · How we verify
elapegademase-lvlr
At a glance
| Generic name | elapegademase-lvlr |
|---|---|
| Also known as | Revcovi |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
- Cough
- Vomiting
- Respiratory infections
- Injection site pain
- Abdominal pain upper
- Arthralgia
- Asthenia
- Diarrhea
- Fatigue
- Nausea
- Rash
- Upper respiratory tract infection
Serious adverse events
- CMV pneumonitis and respiratory failure
- Pulmonary hemorrhage
- Respiratory failure
- Neutropenia
- Convulsion
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- elapegademase-lvlr CI brief — competitive landscape report
- elapegademase-lvlr updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI